2015Zhonghua xiaohua zazhiRequires access

Efficacy of transjugular intrahepatic portosystemic shunt with covered stents in the treatment of portal hypertension in 46 patients with primary hepatocellular carcinoma

Wei Li, Lizhou Wang, Xuegang Yang, Jie Song, Tianpeng Jiang, Jidong Yang

Open publisher page 0 citations

Abstract

Objective To investigate the efficacy of transjugular intrahepatic portosystemic shunt (TIPS) with covered stent in the treatment of portal hypertension in patients with hepatocellular carcinoma. Methods The clinical data of 46 patients with primary hepatocellular carcinoma and portal hypertension who received TIPS with stent treatment were retrospectively analyzed. After treatment, liver function, shunt patency, re-bleeding rate, hepatic encephalopathy, ascites, gastric intestinal symptoms, lifetime and causes of death were analyzed. Compare t test was performed for measurement data comparison among groups. The survival curves were used to analyse the cumulative stent shunt patency rate, the incidence of hepatic encephalopathy and the survival rate. Results After the operation, portal vein pressure significantly decreased compared with that before operation [(16.2±4.6) mmHg vs (28.3±5.1) mmHg, 1 mmHg=0.133 kPa], and the difference was statistically significant (t=21.30, P 0.05]. Cumulative stent shunt patency at 3, 6, 12, 24, 36 month after operation was 100.0%, 95.6%, 93.5%, 91.3% and 91.3%, respectively. The cumulative incidence of hepatic encephalopathy was 6.5%, 8.7%, 13.0%, 17.4% and 26.1%, respectively; cumulative survival rate was 95.7%, 82.6%, 67.4%, 43.5% and 32.6%, respectively. In 10 cases of refractory ascites, ascites of all the patients reduced with different degree after operation and gastrointestinal uncomfortable symptoms were relieved. Conclusion In patients with primary hepatocellular carcinoma and portal hypertension, who have gastrointestinal bleeding or refractory ascites, treatment of TIPS with covered stents could effectively lower portal pressure, prevent re-bleeding and reduce the volume of ascites. Key words: Portosystemic shunt, transjugular intrahepatic; Primary hepatocellular carcinoma; Liver cirrhosis; Hypertension, portal

About this research paper

What this paper is about

Objective To investigate the efficacy of transjugular intrahepatic portosystemic shunt (TIPS) with covered stent in the treatment of portal hypertension in patients with hepatocellular carcinoma. Methods The clinical data of 46 patients with primary hepatocellular carcinoma and portal hypertension who received TIPS with stent treatment were retrospectively analyzed. After treatment, liver function, shunt patency, re-bleeding rate, hepatic encephalopathy, ascites, gastric intestinal symptoms, lifetime and causes of death were analyzed. Compare t test was performed for measurement data comparison among groups. The survival curves were used to analyse the cumulative stent shunt patency rate, the incidence of hepatic encephalopathy and the survival rate. Results After the operation, portal vein pressure significantly decreased compared with that before operation [(16.2±4.6) mmHg vs (28.3±5.1) mmHg, 1 mmHg=0.133 kPa], and the difference was statistically significant (t=21.30, P 0.05]. Cumulative stent shunt patency at 3, 6, 12, 24, 36 month after operation was 100.0%, 95.6%, 93.5%, 91.3% and 91.3%, respectively. The cumulative incidence of hepatic encephalopathy was 6.5%, 8.7%, 13.0%, 17.4% and 26.1%, respectively; cumulative survival rate was 95.7%, 82.6%, 67.4%, 43.5% and 32.6%, respectively. In 10 cases of refractory ascites, ascites of all the patients reduced with different degree after operation and gastrointestinal uncomfortable symptoms were relieved. Conclusion In patients with primary hepatocellular carcinoma and portal hypertension, who have gastrointestinal bleeding or refractory ascites, treatment of TIPS with covered stents could effectively lower portal pressure, prevent re-bleeding and reduce the volume of ascites. Key words: Portosystemic shunt, transjugular intrahepatic; Primary hepatocellular carcinoma; Liver cirrhosis; Hypertension, portal

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To investigate the efficacy of transjugular intrahepatic portosystemic shunt (TIPS) with covered stent in the treatment of portal hypertension in patients with hepatocellular carcinoma. Methods The clinical data of 46 patients with primary hepatocellular carcinoma and portal hypertension who received TIPS with stent treatment were retrospectively analyzed. After treatment, liver function, shunt patency, re-bleeding rate, hepatic encephalopathy, ascites, gastric intestinal symptoms, lifetime and causes of death were analyzed. Compare t test was performed for measurement data comparison among groups. The survival curves were used to analyse the cumulative stent shunt patency rate, the incidence of hepatic encephalopathy and the survival rate. Results After the operation, portal vein pressure significantly decreased compared with that before operation [(16.2±4.6) mmHg vs (28.3±5.1) mmHg, 1 mmHg=0.133 kPa], and the difference was statistically significant (t=21.30, P 0.05]. Cumulative stent shunt patency at 3, 6, 12, 24, 36 month after operation was 100.0%, 95.6%, 93.5%, 91.3% and 91.3%, respectively. The cumulative incidence of hepatic encephalopathy was 6.5%, 8.7%, 13.0%, 17.4% and 26.1%, respectively; cumulative survival rate was 95.7%, 82.6%, 67.4%, 43.5% and 32.6%, respectively. In 10 cases of refractory ascites, ascites of all the patients reduced with different degree after operation and gastrointestinal uncomfortable symptoms were relieved. Conclusion In patients with primary hepatocellular carcinoma and portal hypertension, who have gastrointestinal bleeding or refractory ascites, treatment of TIPS with covered stents could effectively lower portal pressure, prevent re-bleeding and reduce the volume of ascites. Key words: Portosystemic shunt, transjugular intrahepatic; Primary hepatocellular carcinoma; Liver cirrhosis; Hypertension, portal

Key concepts: Medicine, Ascites, Portal hypertension, Hepatic encephalopathy, Transjugular intrahepatic portosystemic shunt, Hepatocellular carcinoma, Gastroenterology, Stent

Related papers

Back to paper searchBrowse research topicsOriginal source
Efficacy of transjugular intrahepatic portosystemic shunt with covered stents in the treatment of portal hypertension in 46 patients with primary hepatocellular carcinoma — Research Paper | ScholarLens